Fig. 2: Sum of autoantibody levels. | Nature Communications

Fig. 2: Sum of autoantibody levels.

From: Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial

Fig. 2: Sum of autoantibody levels.

A The sum of autoantibody levels (SAL) in systemic sclerosis (SSc; n = 45) at the baseline and healthy controls (HCs; n = 45). P values were calculated by two-sided Mann-Whitney’s U test. B Absolute change of mRSS in SSc patients during the DESIREs trial before and after rituximab (RTX) or placebo administration (week 0 and week 24). HR: high responder, LR: low responder. C SAL before and after the study period of the DESIRES trial by the treatment arm (placebo week 0: n = 21, placebo week 24: n = 21, RTX HR week 0: n = 11, RTX HR week 24: n = 11, RTX LR week 0: n = 13, RTX LR week 24: n = 13). P values were calculated by two-sided Mann–Whitney’s U test. D Serum levels of SSc-related autoantibodies before and after the study period of the DESIRES trial by the treatment arm (placebo week 0: n = 21, placebo week 24: n = 21, RTX HR week 0: n = 11, RTX HR week 24: n = 11, RTX LR week 0: n = 13, RTX LR week 24: n = 13). ATA anti-topoisomerase I antibody, ACA anti-centromere antibody, ARA anti-RNA polymerase III antibody.

Back to article page